In July 2026, I was appointed as a member of the Board of Directors and Chief Innovation Officer (CIO) of Morus. After working on new drug development at Otsuka Pharmaceutical and alternative protein development at Beyond Meat in the US, I joined Morus in September 2023, which means it has been more than three years since I came on board. I would like to take this opportunity to reflect on how my encounter with the “silkworm”—a small organism possessing both high-quality protein and abundant functional ingredients—has shaped my career.
The origin of my aspiration to develop new drugs stems from having a family member who suffered from an intractable disease during my childhood. The long journey to a diagnosis, followed by the harsh reality upon finally being told that “no cure exists”—that sense of powerlessness is what led me to the field of pharmaceutical development.
At Otsuka Pharmaceutical, I was fortunate to have the opportunity to be involved in all phases of development, from Phase I to Phase III, in both the central nervous system and dermatology fields. In clinical trials, while I witnessed firsthand (through the data collected) the pain experienced by patients, their families, and medical professionals, I also felt the tangible impact of the investigational drugs alleviating symptoms, giving me a real sense that I was helping others. Two of the investigational drugs I worked on were successfully seen through to the end of their trials and gained approval thanks to my former colleagues, mentors, and team members after I left the company. I remain proud to this day of having been part of the mission to deliver new drugs to patients.
As a total healthcare company, Otsuka Pharmaceutical operates broadly from prevention to treatment. In that environment, I began to take an interest in healthy eating habits as a means of “building a body that resists disease.” Around the same time, amid reports of global warming and extreme climate change, I started exploring ways to balance sustainability and health. That was when I encountered Beyond Meat, a startup based in Los Angeles, USA.
At Beyond Meat, as a core member before the company went public, I was involved in every aspect of the business, including research, development, analysis, and quality control of plant-based meat. When I first joined, the organization was still small enough to fit in a single room. The days of sharing project progress with everyone every week, experiencing the highs and lows together, allowed me to understand firsthand what it means to build a business as one united team. It was an exciting time with new deals constantly being finalized and new products continuously being released, but I also witnessed the challenges regarding internal controls and hiring that came with rapid business expansion.
As the COVID-19 pandemic began to subside, I started considering a return to Japan due to family circumstances. While wondering how to proceed with job hunting in Japan while still in the US, I remembered a TV commercial for “BizReach,” a job search platform in Japan, and decided to register. A recruiter from Morus found my profile and reached out to me, which marked the beginning of our connection.
At the time, I had never eaten insects, but a scene featuring an insect protein bar from the movie Snowpiercer, which I had watched during my student days, crossed my mind, and I thought, “The time has finally come.” When I first met with our CEO, Ryo Sato, and learned that silkworms are a resource rich not only in protein but also in abundant functional ingredients, I felt my past experiences in pharmaceuticals and food science connect into a single line. I was also strongly drawn to their unconventional, bold stance of targeting overseas markets from the very beginning, rather than the typical “start in Japan first” approach for a Japanese company. Consequently, I joined Morus in September 2023.
When I met Morus, there were only three employees. Soon after I joined, another person came on board, making it a five-person team. Since this small group had to handle everything from silkworm production, processing, research and development, to sales and marketing, I was drafted into harvesting silkworms right after joining—despite the fact that I hadn’t been able to touch insects since childhood. At first, I worked while holding back screams and tears (though some screams definitely slipped out), but I managed to get through it with a “double-glove strategy.” Later, I also had the opportunity to systematically learn the basics of sericulture as part of the 10th cohort of the Sericulture School hosted by the Gunma Sericultural Technology Center. It was a daily process of trial and error, but I think it was actually the perfect environment for my nature of wanting to try everything myself and wanting to think about the entire business based on a deep understanding of the operations on the ground.
Until now, I have overseen the entire R&D domain, including production collaboration with sericulture farmers, silkworm production in our own facilities, mass production technology research, powderization method optimization, product development, quality control, regulatory and export compliance, and intellectual property strategy.
We project that sales volume for the next two years can be met through collaboration with existing sericulture farmers and our own in-house production. However, with an eye toward further sales expansion, we are currently establishing a production system to increase our silkworm production capacity to five times its current level. We plan to visualize the entire process, including the cultivation of mulberry trees for silkworm feed, and systematically optimize each section, such as the securing of mulberry fields, the development of rearing facilities, and designing processing equipment. Since the cooperation of the national government, local municipalities, affiliated companies, and local residents is essential to achieving this goal, our CEO is taking the lead in building networks in candidate locations.
The effect of 1-deoxynojirimycin (iminosugar)—a silkworm-derived compound for which we have already established our own evidence in suppressing blood sugar spikes—is currently being rolled out mainly in Singapore, as a preventive medicine option for the globally increasing population of diabetics and pre-diabetics. We believe that delivering a resource originating in Japan to the rest of the world will also contribute to strengthening Japan’s nutritional self-sufficiency. In the future, we intend to continue our internal verification of functional nutrients in silkworms in addition to iminosugars, aiming to solve global health issues with silkworms from Japan as a one-stop solution capable of addressing multiple health challenges.
Morus has four core values: “Bold yet Precise,” “Look Outward,” “Open & Fair,” and “Sound Mind & Body.” All of these align deeply with my own personal principles and are one of the reasons I am at Morus.
This means taking bold steps forward in business without hesitation, while thoroughly building science-based evidence in R&D—balancing both aspects. When I studied in the US as a student, I realized the immense trust placed in the “JAPAN brand” built upon Japanese integrity, but I also noticed a tendency in Japan to be slow in taking on new challenges due to an excessive pursuit of perfection. By simply “giving it a try,” the distance between you and the rest of the world shrinks instantly. Ensuring the crucial points are covered without getting overly bogged down in the minor details is a stance I value highly in life.
This refers to the attitude of thinking globally, unconstrained by conventional wisdom. From the time of its founding, Morus has targeted overseas markets as its main battleground. It is an organization gathering members who possess the perspective of “Which country in the world do we start?” rather than “Let’s start in Japan first.” Having moved back and forth between Japan and the US, this outwardly tuned perspective was something I could naturally share and embrace.
This means exchanging opinions frankly, regardless of title or years of experience. Hierarchy is unnecessary for innovation, and I consider it a duty as a Morus member to voice one’s own opinions. First, everyone communicates what is on their mind. We debate based on various opinions, and then make a decision. Once a conclusion is reached, we charge forward together. I believe that dialogue transcending rank is what breeds trust and builds a strong organization.
This is the belief that keeping oneself in good condition and continuing to be a healthy presence in society is the driving force that produces essential results. I believe that one can only unleash their maximum potential by first being healthy oneself, and by maintaining a clear distinction between working and resting. If you are not at your best, you cannot inspire those around you.
From new drug development to alternative proteins, and finally to silkworms—looking back, it may seem like a roundabout path, but to me, it has been a consistent journey. I look forward to continuing to work with my colleagues to shape the vast potential hidden within the tiny silkworm, one step at a time, supporting the future of the world through Japanese tradition.
The video interview sharing her perspective is now available on YouTube.
It explores the realities of navigating a startup environment and the strategic vision behind his decision to join Morus.
We are hiring! Contact us to hear more about our open positions.